FDA-cleared profile

OptimMRI

RebrAIn, SAS · MRI · FDA-cleared (510(k))

Authorized purpose: OptimMRI processes preoperative DICOM-compatible MR images to generate three-dimensional annotated brain models that aid neurosurgical functional planning and may aid localization of the subthalamic nuclei and ventral intermediate nucleus regions when used with other clinical methods.

Clinical role
Diagnostic magnetic-resonance image acquisition and display, with release-specific reconstruction or derived-image functions where labeled.
Images and patients
MRI · Brain, including the subthalamic nuclei and ventral intermediate nucleus regions of interest
Key limitation
Keep in mind: Use only the exact labeled scanner, field strength, coils, sequences, contrast conditions, patient population, and anatomy; images require trained-physician interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: OptimMRI processes preoperative DICOM-compatible MR images to generate three-dimensional annotated brain models that aid neurosurgical functional planning and may aid localization of the subthalamic nuclei and ventral intermediate nucleus regions when used with other clinical methods.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain, including the subthalamic nuclei and ventral intermediate nucleus regions of interest Input: Supported MR acquisitions, pulse sequences, coils, and optional contrast agents within the exact labeled configuration.
  • Who uses it?Intended users: Appropriately trained healthcare professionals, with image interpretation by a trained physician where stated in the exact labeling.
  • What does the software produce?Output: Cross-sectional MR images and, where labeled, spectra, parametric maps, dynamic images, or derived physical parameters for professional interpretation.
  • What is its most important limitation?Key limitation: Use only the exact labeled scanner, field strength, coils, sequences, contrast conditions, patient population, and anatomy; images require trained-physician interpretation.

Clinical takeaway. Clinical role: OptimMRI processes preoperative DICOM-compatible MR images to generate three-dimensional annotated brain models that aid neurosurgical functional planning and may aid localization of the subthalamic nuclei and ventral intermediate nucleus regions when used with other clinical methods.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a segmentation accuracy evaluation comparing OptimMRI with previously cleared commercially available comparable software tools: 44 cerebral MRIs (88 hemispheres) retrospectively annotated for the STN performance study and 31 cerebral MRIs (62 hemispheres) for the VIM study, with segmentation performed by qualified and experienced medical professionals. At least 90% of surface distances of STN or VIM were not greater than 2.0mm, and all validation criteria were met. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
OptimMRI processes preoperative DICOM-compatible MR images to generate three-dimensional annotated brain models that aid neurosurgical functional planning and may aid localization of the subthalamic nuclei and ventral intermediate nucleus regions when used with other clinical methods.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Diagnostic magnetic-resonance image acquisition and display, with release-specific reconstruction or derived-image functions where labeled.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported MR acquisitions, pulse sequences, coils, and optional contrast agents within the exact labeled configuration.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Cross-sectional MR images and, where labeled, spectra, parametric maps, dynamic images, or derived physical parameters for professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital, clinic, outpatient, or other labeled clinical MR environment.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Appropriately trained healthcare professionals, with image interpretation by a trained physician where stated in the exact labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use only the exact labeled scanner, field strength, coils, sequences, contrast conditions, patient population, and anatomy; images require trained-physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a segmentation accuracy evaluation comparing OptimMRI with previously cleared commercially available comparable software tools: 44 cerebral MRIs (88 hemispheres) retrospectively annotated for the STN performance study and 31 cerebral MRIs (62 hemispheres) for the VIM study, with segmentation performed by qualified and experienced medical professionals. At least 90% of surface distances of STN or VIM were not greater than 2.0mm, and all validation criteria were met. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Accuracy of segmentations for OptimMRI was compared to previously cleared commercially available comparable software tools." … "A total of 44 cerebral MRIs (88 hemispheres) were retrospectively annotated for the STN performance study, and 31 cerebral MRIs (62 hemispheres) were used for the VIM study.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a segmentation accuracy evaluation comparing OptimMRI with previously cleared commercially available comparable software tools: 44 cerebral MRIs (88 hemispheres) retrospectively annotated for the STN performance study and 31 cerebral MRIs (62 hemispheres) for the VIM study, with segmentation performed by qualified and experienced medical professionals. At least 90% of surface distances of STN or VIM were not greater than 2.0mm, and all validation criteria were met. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Accuracy of segmentations for OptimMRI was compared to previously cleared commercially available comparable software tools." … "A total of 44 cerebral MRIs (88 hemispheres) were retrospectively annotated for the STN performance study, and 31 cerebral MRIs (62 hemispheres) were used for the VIM study.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K230150

  • DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K230150; this is regulatory evidence, not an independent clinical effectiveness study.
  • PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K230150; a broader clinical population is not established here.
  • Scopeexact submission
  • Tested versionOptimMRI (K230150)
  • IndependenceSponsor or vendor study

K230150

The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported MR acquisitions, pulse sequences, coils, and optional contrast agents within the exact labeled configuration.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K230150: OptimMRI

  2. Routing

    Source context, not route validation: The exact FDA indication specifies DICOM-compatible MR input; local import, export, identity, display, and neurosurgical planning workflow require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K230150: OptimMRI

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Cross-sectional MR images and, where labeled, spectra, parametric maps, dynamic images, or derived physical parameters for professional interpretation.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K230150: OptimMRI

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional MR images and, where labeled, spectra, parametric maps, dynamic images, or derived physical parameters for professional interpretation.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K230150: OptimMRI

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact FDA indication specifies DICOM-compatible MR input; local import, export, identity, display, and neurosurgical planning workflow require confirmation.
  • Exact FDA submission
  • Checked 2026-09-04

Workflow role

Diagnostic magnetic-resonance image acquisition and display, with release-specific reconstruction or derived-image functions where labeled.

exact submission · checked 2026-09-04

Submission-anchored workflow summary, not a local acceptance or deployment result.

Input

Supported MR acquisitions, pulse sequences, coils, and optional contrast agents within the exact labeled configuration.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Cross-sectional MR images and, where labeled, spectra, parametric maps, dynamic images, or derived physical parameters for professional interpretation.

exact submission · checked 2026-09-04

Output review, editing, approval, export, and downstream use remain release- and site-specific.

Deployment evidence

Exact deployment topology and operational boundaries remain unestablished.

exact submission · checked 2026-09-04

Confirm hosting, PHI flow, retention, access, updates, downtime, and support obligations before procurement or clinical use.

Integration evidence

The exact FDA indication specifies DICOM-compatible MR input; local import, export, identity, display, and neurosurgical planning workflow require confirmation.

exact submission · checked 2026-09-04

Validate the local workflow against the exact release and enabled options.

Vendor family context

Current vendor material is product-family context for K230150 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K230150
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Brain, including the subthalamic nuclei and ventral intermediate nucleus regions of interest
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-07-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K230150: OptimMRI

    U.S. Food and Drug Administration - Published 2023-07-21 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RebrAIn neurosurgical planning family context

    RebrAIn - Accessed 2026-09-04

    Scope: productFamilyContext

Research history

  1. K230150 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253690

LungMaps

Siemens Healthineers AG

Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.

Modality
MRI
Anatomy
Chest/Lung
Decision
2026-06-15
FDA-cleared K260113

uMR Astra

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMR Astra is a diagnostic MR system for cross-sectional and spectroscopic imaging of the labeled head, body, and extremities.

Modality
MRI
Anatomy
Head; body; and extremities
Decision
2026-05-22
FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history